BMS-986497 (ORM-6151)
Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
What will happen during the trial?
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 105 patients (estimated)
- Sponsors
- Bristol Myers Squibb
- Tags
- GSPT1 Degrader, CD33
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1914
- NCT Identifier
- NCT06419634
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.